Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» ASTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ASTX Guru Trades in Q1 2013

Steven Cohen 18,800 sh (New)
Chuck Royce 12,300 sh (unchged)
Jim Simons 469,025 sh (-5.52%)
Zeke Ashton 370,000 sh (-7.5%)
» More
Q2 2013

ASTX Guru Trades in Q2 2013

Paul Tudor Jones 42,700 sh (New)
Jim Simons 962,071 sh (+105.12%)
Steven Cohen 21,079 sh (+12.12%)
Chuck Royce 12,300 sh (unchged)
Zeke Ashton 370,000 sh (unchged)
» More
Q3 2013

ASTX Guru Trades in Q3 2013

Mario Gabelli 157,573 sh (New)
Chuck Royce Sold Out
Zeke Ashton Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 569,470 sh (-40.81%)
» More
Q4 2013

ASTX Guru Trades in Q4 2013

Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ASTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-12-31 Sold Out 0.01%$8.48 - $8.63 $ 8.50%0
Mario Gabelli 2013-09-30 New Buy0.01%$4.43 - $8.86 $ 8.534%157573
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Astex Pharmaceuticals Inc was incorporated in March 1991 as a California corporation and changed its state of incorporation to Delaware in May 1997. It changed its name from SuperGen, Inc. to Astex Pharmaceuticals, Inc. in September 2011. The Company is a pharmaceutical Company dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology and hematology. It is developing a pipeline of novel medicines for partnership with pharmaceutical companies. In July 2011, it completed the acquisition of Astex Therapeutics Limited ('ATL'), a privately held UK-based biotechnology company with particular expertise in fragment-based drug discovery. ATL discovers and develops novel small molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, ATL has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. Its main source of revenue is royalty revenues relating to sales of Dacogen (decitabine) for Injection, and it received additional revenue from various partnered programs as these programs reach predetermined developmental milestones. Its current primary developmental efforts revolve around the products progressing out of its small-molecule drug discovery programs. Its two internal programs are SGI-110, a novel second generation hypomethylating agent, and AT13387, a novel Hsp90 inhibitor. Its competitors include ArQule, Inc., Array BioPharma, Crystal Genomics, Exelixis, Infinity Pharmaceuticals, Daiichi Sankyo Group, Vertex Pharmaceuticals, Sanofi, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly & Co., GSK, Novartis AG, Pfizer, Synta Pharmaceuticals, and others. The Company is subject to FDA laws and regulations and regulation by other agencies under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state or local laws and regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK